Browsing by Author "Waseem, Shamaila"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    A clear approach: Hemostatic gel as a novel adjunct for pediatric upper gastrointestinal bleeding
    (Wolters Kluwer, 2025-02-03) Plott, Natalia; Rougraff, Audra; Bose, Paroma; Tolliver, Kyla M.; Waseem, Shamaila; Hoskins, Brett J.; Pediatrics, School of Medicine
    Pediatric upper gastrointestinal bleeding (UGIB) is a significant clinical concern, with a mortality rate of approximately 2%. Endoscopic management of UGIB in children includes various techniques such as injections, mechanical devices, thermal therapies, and topical agents. PuraStat®, a clear hemostatic gel, has been used in adults to create a physical barrier for hemostasis without obscuring the endoscopic view. However, its use in pediatric UGIB has not been well-documented. A review of four pediatric cases where PuraStat® was used to treat UGIB showed that it was applied as an adjunct to other hemostatic methods like clip placement or epinephrine injections, and in one case, as monotherapy for a large duodenal ulcer/site of recently contained perforation. The gel was easy to use, appeared to be beneficial, and was well-tolerated in this small cohort, although conclusions regarding its safety and efficacy are limited by the sample size.
  • Thumbnail Image
    Item
    American Neurogastroenterology and Motility Society (ANMS) Task Force Recommendations for Resumption of Motility Laboratory Operations During the COVID-19 Pandemic
    (American Neurogastro­enterology and Motility Society (ANMS), 2020-05-17) Baker, Jason R.; Moshiree, Baha; Rao, Satish; Neshatian, Leila; Nguyen, Linda; Chey, William D.; Saad, Richard; Garza, Jose; Waseem, Shamaila; Khan, Abraham R.; Pandolfino, John E.; Gyawali, C. Prakash; Department of Pediatrics, IU School of Medicine
    The ANMS organized a Task Force for developing guidance strategies regarding re-opening of motility laboratories. This document describes how to stratify urgency of motility physiologic procedures, screen prior to the procedures, optimize personal protective equipment (PPE) utilization, clean and prepare the motility laboratory space during the COVID-19 pandemic.
  • Thumbnail Image
    Item
    A comprehensive review of functional dyspepsia in pediatrics
    (Springer, 2022-02) Waseem, Shamaila; Rubin, Logan; Pediatrics, School of Medicine
    Functional gastrointestinal disorders have been known as a diagnosis of exclusion since the Rome Foundation first created these criteria in 1990. Since that time, a large amount of research and clinical data has better clarified the mechanisms and treatment options for these. Functional dyspepsia is caused by physiologic, genetic, environmental, and psychological factors, as well as various functional abnormalities, such as increased sensitivity to acid, increased sensitivity to duodenal lipids and low-grade inflammation. This disorder has significant symptom overlap between other functional disorders, such as irritable bowel syndrome and gastroparesis, but has differential criteria and two new subclasses: postprandial distress syndrome and epigastric pain syndrome. Diagnosis of functional dyspepsia should be based upon appropriate clinical evaluation in tandem with Rome IV criteria. In recent years, many treatment measures for functional dyspepsia have been studied, such as pharmacologic intervention, behavioral therapy, or alternative therapy, an example being hypnotherapy. These treatment measures have proven to be effective in symptom reduction in pediatrics. Though this disorder is functional, it has been shown to cause a significant impact on pediatric patients' quality of life continuing into adulthood.
  • Thumbnail Image
    Item
    Effect of Octreotide on the Colonic Motility in Pediatric Patients with Chronic Recalcitrant Constipation
    (Lippincott, Williams, and Wilkins, 2015-12) Parashette, Kalyan Ray; Waseem, Shamaila; Horn, Debra; Shah, Aali; Croffie, Joseph; Department of Pediatrics, IU School of Medicine
    Objective: The aim of the present study was to study the effect of octreotide on colonic motility in pediatric patients with recalcitrant chronic constipation/encopresis and other suspected colonic motility disorders. Methods: This was a nonrandomized, single-center, open-label, prospective study evaluating the effect of a single subcutaneous dose of octreotide on colonic motility. Results: Thirteen patients (5 boys) were enrolled in the study. The age range was 4.6 to 16.2 years. Eleven patients (84%) had normal colonic manometry and 2 patients (16%) had colonic neuropathy. Motility Index (MI) (mmHg) for the 15 minutes before and after octreotide infusion was 6.03 ± 1.26 (95% confidence interval [CI] 5.35–6.72) and 5.32 ± 1.66 (95% CI 4.42–6.23), respectively, with P value of 0.08. MI for the 30 minutes before and after octreotide infusion was 6.89 ± 1.37 (95% CI 6.14–7.64) and 6.71 ± 1.47 (95% CI 5.91–7.52), respectively, with P value of 0.55. MI for the 45 minutes before and after octreotide infusion was 7.73 ± 1.32 (95% CI 7.01–8.45) and 7.53 ± 1.38 (95% CI 6.78–8.28), respectively, with P value of 0.8. Conclusion: Our study showed that the administration of octreotide resulted in no significant changes in colonic MI in pediatric patients with chronic recalcitrant constipation.
  • Thumbnail Image
    Item
    Response to Richter and Vaezi
    (Wolters Kluwer, 2021-01) Gyawali, C. Prakash; Baker, Jason R.; Moshiree, Baha; Rao, Satish; Neshatian, Leila; Nguyen, Linda; Chey, William D.; Saad, Richard; Garza, Jose M.; Waseem, Shamaila; Khan, Abraham R.; Pandolfino, John E.; Pediatrics, School of Medicine